Cabazitaxel
 |
| Systematic (IUPAC) name |
| (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-ene-2-yl benzoate |
| Clinical data |
| Trade names |
Jevtana |
| AHFS/Drugs.com |
Consumer Drug Information |
| MedlinePlus |
a611009 |
| Licence data |
EMA:Link, US FDA:link |
| Pregnancy cat. |
D (US) |
| Legal status |
POM (UK) ℞-only (US) |
| Routes |
Intravenous |
| Identifiers |
| CAS number |
183133-96-2  N |
| ATC code |
L01CD04 |
| PubChem |
CID 9854073 |
| DrugBank |
DB06772 |
| ChemSpider |
8029779  Y |
| UNII |
51F690397J Y |
| ChEBI |
CHEBI:63584 Y |
| ChEMBL |
CHEMBL1201748 N |
| Chemical data |
| Formula |
C45H57NO14 |
| Mol. mass |
835.93 g/mol |
- CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC
|
-
InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35, N
Key:BMQGVNUXMIRLCK-OAGWZNDDSA-N Y
|
 N (what is this?) (verify)
|
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid.[1] It was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.[2]
Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
Clinical trials [edit]
In a phase III trial with 755 men for the treatment of castrate-resistant prostate cancer, median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving mitoxantrone. Cabazitaxel was associated with more grade 3-4 neutropenia (81.7%) than mitoxantrone (58%).[3]
References [edit]
External links [edit]
(what is this?) (verify)
